Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.14 (14.583%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Directorate Change

4 May 2007 14:35

Provexis PLC04 May 2007 4 May 2007 PROVEXIS PLC ("Provexis" or the "Company") Directorate Change Provexis plc (ticker PXS.L), the nutraceutical company that developsscientifically-proven functional and medical foods, has appointed Jonathan BrettDiggines to its Board as a non-executive director with immediate effect. Jonathan Diggines, 54, is Chief Executive Officer of Enterprise Ventures GroupLimited, a 19.4 per cent shareholder in the Company. Jonathan, who is asolicitor, joined Enterprise Ventures in 2005 and had previously spent 10 yearsas Managing Director of Murray Johnstone Private Equity where he managedsubstantial private equity and venture funds. Jonathan holds or has held thefollowing directorships or been a partner in the following partnerships withinthe five years prior to this announcement: • Enterprise Ventures (General Partner Coalfields) Limited • Enterprise Ventures (General Partner EVF/LEV) Limited • Enterprise Ventures (General Partner HSBC European Fund) Limited • Enterprise Ventures (General Partner HSBC UK Enterprise Fund) Limited • Enterprise Ventures (General Partner Rising Stars) Limited • Enterprise Ventures (General Partner Rising Stars II) Limited • Enterprise Ventures Limited • Enterprise Ventures Group Limited • Enterprise Ventures Nominees Limited • LE Founders Limited • LE Founders II Limited • LE Founders III Limited • Nichols plc • North West Enterprise Investment Limited • Rising Stars Growth Fund Limited • Carbutt & Co. (1928) Limited • LE Founders Limited • MJPAP (Syndications) Limited • MJPAP II (Syndications) Limited • T F Willow Limited • Weigh A Way Limited • W F P Willow Limited • W G Willow Limited • W I Willow Limited • W Willow Limited • British Venture Capital Association • RAL (S&G) Limited • Sumit Venture Fund One Limited • STF Management Limited • SEV Investments Limited • SEV Holdings Limited • BIG (General Partner) Limited • Regent Street Ventures Limited • Aberdeen Murray Johnstone Private Equity Limited • Euractions Management Limited • Murray Johnstone Limited • Callform Limited • Aberdeen Growth Opportunities VCT PLC • M J Founders Limited • COIP (GB) Limited • Aberdeen Asset Managers Limited • AMJPEF Founder Partner Limited • AMJPEF GP Limited There are no further disclosures to be made in accordance with Schedule 2(g) ofthe AIM Rules. Dawson Buck, Chairman of Provexis said: "I am delighted that Jonathan Diggineshas joined the Board of Provexis. He brings a considerable wealth of experiencegained from his management of venture funds and from his portfolio ofnon-executive director roles both in public and private companies, including anumber of significant food and drink sector investments. These attributescombined with his standing in the private equity and venture capital industrywill add significant value to the strategic development of our proprietarytechnologies." - ENDS - Enquiries: Provexis PlcStephen Moon, Chief Executive Officer 020 8392 6634 Arbuthnot SecuritiesTom GriffithsAlasdair Younie 020 7012 2000 Adventis Financial PRChris Steele 020 7034 4759Annie Evangeli 020 7034 4757 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
20th May 20267:00 amRNSHolding(s) in Company
16th Apr 202612:37 pmRNSHolding(s) in Company
31st Dec 20258:22 amRNSHalf-year Financial Report
31st Dec 20258:22 amRNSHalf-year Financial Report
21st Nov 20251:38 pmRNSResult of AGM
30th Oct 20257:30 amRNSRestoration - Provexis plc
30th Oct 20257:00 amRNSFinal Results
1st Oct 20257:30 amRNSSuspension - Provexis PLC
30th Sep 20258:40 amRNSDelay in publication of annual accounts
7th Jan 20251:14 pmRNSGrant of Options and Warrants
31st Dec 20241:00 pmRNSTotal Voting Rights
31st Dec 20249:59 amRNSHalf-year Report
18th Dec 20247:00 amRNSPurchase of Fruitflow® II SD & royalty payment
25th Oct 20243:47 pmRNSResult of AGM
30th Sep 20247:00 amRNSFinal Results
30th Apr 20245:00 pmRNSTotal Voting Rights
28th Mar 20247:00 amRNSIssue of Equity - purchase of Fruitflow® II SD
29th Dec 202312:48 pmRNSHalf-year Report
26th Oct 20231:51 pmRNSResult of AGM
29th Sep 20237:00 amRNSFinal Results
30th Aug 20237:04 amRNSBYHEALTH regulatory filing with Chinese SAMR
3rd Apr 20237:00 amRNSCapital structure and funding update
24th Jan 202311:03 amRNSGrant of Share Options
30th Dec 20228:53 amRNSHalf-year Report
27th Oct 20221:12 pmRNSResult of AGM
14th Oct 20227:00 amRNSDirectorate Change
30th Sep 20227:00 amRNSFinal Results
22nd Jun 20227:00 amRNSTwo new agreements with DSM & patent application
31st May 20225:00 pmRNSTotal Voting Rights
17th May 202212:39 pmRNSExercise of Options and Total Voting Rights
31st Dec 20217:00 amRNSHalf-year Report
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
4th Nov 20211:30 pmRNSResult of AGM
4th Nov 202111:07 amRNSBy-Health Fruitflow agreement and support in R&D
1st Oct 20216:04 pmRNSGrant of Share Options
30th Sep 20217:00 amRNSFinal Results
9th Sep 20214:41 pmRNSSecond Price Monitoring Extn
9th Sep 20214:35 pmRNSPrice Monitoring Extension
24th Aug 20214:35 pmRNSPrice Monitoring Extension
22nd Jul 20214:40 pmRNSSecond Price Monitoring Extn
22nd Jul 20214:35 pmRNSPrice Monitoring Extension
21st Jul 20214:41 pmRNSSecond Price Monitoring Extn
21st Jul 20214:36 pmRNSPrice Monitoring Extension
5th Jul 20214:35 pmRNSPrice Monitoring Extension
1st Jul 20214:40 pmRNSSecond Price Monitoring Extn
1st Jul 20214:35 pmRNSPrice Monitoring Extension
26th Feb 20215:00 pmRNSTotal Voting Rights
19th Feb 20217:30 amRNSDirector / PDMR notification
19th Feb 20217:00 amRNSPlacing of new ordinary shares to raise £50,000

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.